Biosight is developing innovative therapeutics for hematological malignancies and disorders.

Our lead product, aspacytarabine (BST-236), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity.


As such, BST-236 may serve as an ideal therapy for leukemia, particularly for delivering high doses of cytarabine to medically unfit or older adults who otherwise cannot be treated by effective doses of chemotherapy.


BST-236 is being investigated as a single-agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS):

Aspacytarabine pipeline.png